An exploratory pilot study with copeptin as a biomarker for individualizing treatment for nocturnal polyuria

The aim of the present study was to investigate the use of random copeptin concentrations as possible biomarkers for the differential diagnosis of nocturnal polyuria (NP).

In all, 111 patients with and without nocturia were enrolled in the study. Patients with a neurogenic bladder and/or those who had undergone bladder or urethral surgery were excluded from the study. All patients completed a 72-hour frequency-volume chart and a renal function profile. A random blood sample was obtained during the day for measurement of plasma copeptin concentrations, osmolality, and serum sodium and creatinine concentrations. The effect of the use of different definitions for NP was evaluated.

The median age of the study participants was 61 years, and 48% were female. Copeptin was significantly correlated with urinary and plasma osmolality, as well as free water clearance (r=0.43, 0.56 and -0.38 respectively; P < .001 for all). Study participants were divided into 3 groups: controls (n = 51), those with NP (n = 41), and those with global polyuria (n = 19). Copeptin concentrations were significantly lower in subjects with global polyuria than in those with NP and the control group (2.96 vs 3.97 and 3.94 pM, respectively; P = .008 and .005). There was no significant difference in random daytime copeptin concentrations between the NP and control groups (P = .972). The results differed when other definitions for NP were used (e.g. NPi33 or NUP10).

We could not confirm our hypothesis that patients with NP have lower copeptin concentrations, although random blood sampling is not ideal. Further research is required to determine the use of copeptin in NP, perhaps in the identification of the desmopressin response.

Lower urinary tract symptoms. 2017 Oct 23 [Epub ahead of print]

Elke Bruneel, An-Sofie Goessaert, Marie-Astrid Denys, Kristian V Juul, Jens P Nørgaard, Karel Everaert

Department of Urology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium., Ferring Pharmaceuticals AS, 11 Kay Fiskers Plads, DK-2300 Copenhagen S, Denmark.

Pelvic Health Weekly Newsletter